Name: Entrada Therapeutics, Inc. (TRDA) Financial Statements
Creator: FinSpry

Entrada Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Entrada Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	210.78	129.01	0.00	0.00	0.00
Cost of Revenue	125.31	99.88	66.61	35.93	0.00
Gross Profit	85.48	29.13	-66.61	-35.93	0.00
Operating Expenses
Research & Development	125.31	99.88	66.61	35.93	21.10
Selling, General & Administrative	38.47	32.29	30.64	15.20	5.57
Operating Expenses	163.77	132.18	97.25	51.13	26.67
Operating Income	47.01	-3.16	-97.25	-51.13	-26.67
Other Income/Expense
Interest Income	19.47	15.22	2.63	0.04	0.16
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	19.47	0.00	-2.63	0.03	0.00
Income
Income Before Tax	66.49	12.06	-94.62	-51.16	-26.52
Income Tax Expense	0.86	18.74	0.00	0.00	0.00
Net Income	65.63	-6.69	-94.62	-51.16	-26.52
Net Income - Continuous Operations	65.63	-6.69	-94.62	-51.16	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	50.78	-0.32	-95.35	-50.06	-26.34
EBIT	47.01	-3.16	-97.25	-51.16	-26.67
Depreciation & Amortization	3.77	2.84	1.90	1.12	0.33
Earnings Per Share
Basic EPS	2.00	-	-3.00	-8.00	-24.00
Diluted EPS	2.00	-	-3.00	-8.00	-24.00
Basic Shares Outstanding	37.31	33.05	31.29	6.27	1.11
Diluted Shares Outstanding	39.00	33.05	31.29	6.27	1.11